Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Verastem Inc.

An update from Verastem ( ($VSTM) ) is now available. On November 13, 2025, Verastem, Inc. entered into an underwriting agreement with Jefferies LL...

Verastem Announces Public Offering to Raise $96.9 Million

In a report released yesterday, Leonid Timashev from RBC Capital maintained a Buy rating on Verastem, with a price target of $14.00. According to T...

Current Quarter	$-0.44	Next Quarter	$-0.63
Current Year	$-3.24	Next Year	$-2.17
QoQ Growth	-43.2%	YoY Growth	+33.0%
3Y EPS CAGR	+9.4%	Target Price	$16.00
Consensus	Buy	Upside	+60.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VSTM	$10.00	+1.94%	2.46M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VSTM	$10.00	+1.9%	2.46M
3
4
5
6

VSTM

VSTM

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Verastem Inc. Data in Excel

Get Verastem Inc. Data in Excel